Dec 18, 2025 | Clinical Outcomes, News
Abstract Introduction Intravenous immune globulin 10% liquid (IVIG 10%) is used in the treatment of primary immunodeficiency (PID). Originally approved in 2012 and then voluntarily withdrawn in 2016, IVIG 10% (BIVIGAM®) underwent manufacturing process improvements by...
Dec 3, 2025 | Clinical Outcomes, News
Abstract Introduction Atherosclerotic cardiovascular disease (ASCVD) is a global health concern. Reducing low-density lipoprotein cholesterol (LDL-C) is critical in ASCVD prevention and treatment. Inclisiran, a novel RNA therapeutic agent, offers a promising solution...
Oct 27, 2026 | Clinical Outcomes
Presented at IDWeek 2026 Authors: Lucinda J. Van Anglen, PharmD Christina J. Weeks, PharmD Jazmin Duque, PhD, MPH Richard F. Herrscher, MD View Poster
Oct 27, 2026 | Clinical Outcomes
Presented at IDWeek 2026 Authors: Lucinda J. Van Anglen, BS, PharmD, FIDSA Richard Hengel, MD, FIDSA Brian S. Metzger, MD, MPH Thomas K. Sleweon, MD Erika M. Young, DO Jorge R. Bernett, MD Stacey E. Baker, MD Anurag Duggal, MD Quyen Luu, MD Richard Prokesch, MD, FIDSA...
Oct 27, 2026 | Clinical Outcomes
Presented at IDWeek 2026 Authors: Nikhil K. Bhayani, MD, FIDSA Richard Prokesch, MD, FIDSA Richard Hengel, MD, FIDSA Thomas K. Sleweon, MD Erika M. Young, DO Quyen Luu, MD Brian S. Metzger, MD, MPH Anurag Duggal, MD Stacey E. Baker, MD Jorge R. Bernett, MD Kimberly A....
Oct 25, 2025 | Clinical Outcomes
Presented at ACG 2025 The Healix Research Team is honored to be showcasing our latest collaborative clinical research with our esteemed physician partners and Ferring Pharmaceuticals at ACG2025 this weekend in Phoenix. If you’re participating in the meeting, we...
Recent Comments